Clinical Progression in Alpha-Synuclein Positive LRRK2-PD and Sporadic Parkinson's Disease: A Longitudinal Analysis.
Clinical Progression in Alpha-Synuclein Positive LRRK2-PD and Sporadic Parkinson's Disease: A Longitudinal Analysis.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Chicago, US · Author affiliation
Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.Location evidence
Iowa City, US · Author affiliation
Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA.Location evidence
Pittsburgh, US · Author affiliation
Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.Location evidence
US · Author affiliation · country only
Berry Consultants, Austin, TX, USA.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
BACKGROUND: LRRK2-Parkinson's disease (LRRK2-PD) is biologically heterogeneous with approximately 30% lacking aggregated alpha synuclein (αSyn) in cerebrospinal fluid by seed amplification assay (SAA). Prior work has suggested slower progression in LRRK2-PD compared to sporadic PD (sPD). OBJECTIVE: We aimed to assess how LRRK2-PD with αSyn aggregates on SAA (S+ LRRK2-PD) compares to S+ sPD. METHODS: Data from the Parkinson's Progression Markers Initiative were used to compare S+ LRRK2-PD and S+ sPD cohorts propensity score-matched on age, disease duration, sex and levodopa equivalent dose (N = 79 per cohort). Baseline clinical and biological features and 4-year longitudinal features were assessed. RESULTS: At baseline, S+ LRRK2-PD participants had lower motor scores and dopaminergic deficit. Among measures showing within group progression, longitudinal trajectories did not differ significantly between groups. CONCLUSIONS: Longitudinal clinical progression of S+ LRRK2-PD and sPD in the PPMI study is similar despite differences in baseline features.